Jaguar Health, Inc.

Is Jaguar Health, Inc. technically bullish or bearish?

As of September 2, 2025, Jaguar Health, Inc. shows a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with year-to-date returns of -92.44% compared to the index's 12.22%.

As of 2 September 2025, the technical trend for Jaguar Health, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mildly bullish. However, the daily moving averages are bearish, and Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. The KST presents a mixed view with a mildly bullish weekly signal but bearish monthly. There is no clear trend indicated by Dow Theory or OBV.<BR><BR>In terms of performance, Jaguar Health has significantly underperformed compared to the S&P 500, with a year-to-date return of -92.44% versus the S&P 500's 12.22%, and a one-year return of -93.05% compared to 17.14% for the index. Overall, the current technical stance is mildly bearish, driven by the bearish daily moving averages and mixed signals from other indicators.

Is Jaguar Health, Inc. overvalued or undervalued?

As of August 9, 2017, Jaguar Health, Inc. is considered overvalued and risky due to its poor financial metrics, including a Price to Book Value of 1.20, an EV to Sales ratio of 3.18, a ROE of -742.25%, and a year-to-date stock performance decline of -89.31%, especially when compared to its peers.

As of 9 August 2017, Jaguar Health, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently overvalued given its financial metrics, including a Price to Book Value of 1.20, an EV to Sales ratio of 3.18, and a staggering ROE of -742.25%. These figures indicate significant financial distress and a lack of profitability, which is further underscored by its loss-making status reflected in the P/E ratio being not applicable.<BR><BR>In comparison to its peers, Jaguar Health, Inc. shows a less favorable position; for instance, SeqLL, Inc. has an EV to EBITDA of -8.8835, while Agile Therapeutics, Inc. has an EV to EBITDA of -0.5982, both indicating more manageable valuations within the same risky category. The company's recent stock performance has been notably poor, with a year-to-date return of -89.31%, contrasting sharply with the S&P 500's modest gain of 2.44% in the same period, reinforcing the notion that Jaguar Health, Inc. is overvalued in its current state.

How big is Jaguar Health, Inc.?

As of Jun 18, Jaguar Health, Inc. has a market capitalization of 4.09 million, with net sales of 11.55 million and a net profit of -40.48 million over the latest four quarters. Shareholder's funds are at 9.77 million, and total assets amount to 53.42 million.

As of Jun 18, Jaguar Health, Inc. has a market capitalization of 4.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 11.55 million, while the sum of net profit for the same period is -40.48 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 9.77 million and total assets at 53.42 million.

What does Jaguar Health, Inc. do?

Jaguar Health, Inc. is a micro-cap pharmaceuticals company focused on developing sustainable gastrointestinal products for humans and animals. As of March 2025, it reported net sales of $2 million and a net loss of $11 million, with a market cap of $4.09 million.

Overview: <BR>Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4.09 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 7.42 <BR>Return on Equity: -742.25% <BR>Price to Book: 0.96<BR><BR>Contact Details: <BR>Address: 200 PINE STREET SUITE 400, SAN FRANCISCO CA: 94104 <BR>Tel: 1 415 3718300 <BR>Fax: 1 302 6555049 <BR>Website: https://jaguar.health/

Should I buy, sell or hold Jaguar Health, Inc.?

Who are in the management team of Jaguar Health, Inc.?

As of March 2022, the management team of Jaguar Health, Inc. includes CEO Lisa Conte, Independent Chairman James Bochnowski, and several Independent Directors: Gregory Divis, John Micek, Jiahao Qiu, and Jonathan Siegel.

As of March 2022, the management team of Jaguar Health, Inc. includes the following individuals:<BR><BR>- Mr. James Bochnowski, who serves as the Independent Chairman of the Board.<BR>- Ms. Lisa Conte, who is the President, Chief Executive Officer, and Director.<BR>- Mr. Gregory Divis, who is an Independent Director.<BR>- Mr. John Micek, who is also an Independent Director.<BR>- Mr. Jiahao Qiu, serving as an Independent Director.<BR>- Mr. Jonathan Siegel, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and independent directors, with Ms. Lisa Conte holding the key position of CEO.